Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2016—Telcor’s QML eLearning interface performs tasks vital to managing point-of-care-testing operators while storing recertification data, such as competency and samples performed together in the company’s QML software for CAP/CMS/JCAHO inspections.
October 2016—Waters Corp. showcased its newest IVD medical device for clinical laboratories, the Acquity UPLC I-Class/Xevo TQ-S micro IVD system. The Xevo TQ-XS is a high-performance tandem quadrupole instrument that aims to expand the scope of ultimate sensitivity analysis.
October 2016—Roche launched its presence by featuring several next-generation diagnostic testing platforms and a virtual reality experience that was designed to give attendees an “under the hood” look at a lab of the future and a concept Roche calls the “Roche connected lab.”
October 2016—Products on display in Ortho Clinical’s booth included the company’s flagship Integrated Clinical Chemistry and Immunodiagnostic Systems and the Nephrocheck Test. The Ortho Vision Max transfusion medicine instrument (shown below), which is pending 510(k) clearance, was highlighted as well.
October 2016—Yaskawa Motoman’s AutoSorter 2000BB bulk sorter has a new configuration available that can maintain frozen specimens in a -20°C environment during the sorting process. The high-speed bulk sorter for high-volume commercial laboratories provides maximum specimen throughput at up to 2,000 tubes per hour.
October 2016—Wheaton launched its DualFusion Vial, which combines properties of plastic and glass into one container. Using plasma enhanced chemical vapor deposition (PECVD) technology, an organosilicate protective layer is fused with a silica-like (SiO2 barrier) layer that is fused to a cyclic olefin polymer (COP) shell to form a robust, covalently bonded material.
October 2016—SpeeDx Pty, Ltd., featured its PlexPCR for the detection of infectious disease pathogens and the ResistancePlus multiplex qPCR test for the detection of Mycoplasma genitalium and antimicrobial resistance markers.
October 2016—Streck and Diesse Diagnostica Senese S.p.A., an Italian manufacturer of in vitro diagnostic systems, are introducing the Diesse Mini-Cube, an automated instrument for erythrocyte sedimentation rate testing in EDTA tubes. Streck will be the exclusive distributor of the Mini-Cube in the United States and Canada.
October 2016—Visiun showcased its predictive analytics and population health reporting, which was added to its flagship product, Performance Insight. The predictive analytics, added to the comprehensive test-use module, are designed to enable laboratories to identify high-risk patients with both elevated patient risk and care gaps.
October 2016—Sekisui Diagnostics and Qualigen announced a strategic partnership encompassing current business and future collaboration opportunities. Sekisui Diagnostics has assumed commercial activities and distribution management for the FastPack IP System and associated products in U.S. and international markets.
